FDA rejects Iluvien, pSivida-Alimera's drug-device eye treatment

January 3, 2011 by MassDevice staff

The Food & Drug Administration turned down pSivida Corp. and Alimera Sciences Inc.'s new drug application for diabetic macular degeneration drug/device combination Iluvien.

PSDV, ALIM logos

pSivida Corp. (NSDQ:PSDV) partner Alimera Sciences Inc. (NSDQ:ALIM) received a rejection letter from the Food & Drug Administration for their drug-device combination Iluvien.

The two companies are developing the system to treat diabetic macular degeneration. The investigational drug delivery system is designed for sustained release of Iluvien with an intra-vitreal insert.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Comments

Built on an AdaptiveTheme using Drupal by Michael Knapp  mknapp